http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2543332-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2407d8ce282e381adc824d5c358d0938 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-14 |
| filingDate | 2011-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6338d75ed1d97f7343a50d6c345ba3c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0161c1d7cb60a8c123d7dd22ca62365f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_982d3b0d8bc45fcd835af59c8fcfeeb2 |
| publicationDate | 2015-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2543332-C2 |
| titleOfInvention | Therapeutic agent for endothelial dysfunction correction |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to medicine, namely to pharmacology and cardiology, and concerns endothelial dysfunction correction. That is ensured by administering a therapeutic agent containing an activated-potentiated form of antibodies to the C-terminal fragment of the AT 1 angiotensin II receptor. n EFFECT: administering this agent provides both the prevention, and effective treatment of endothelial dysfunction to the extent of the complete normalisation of the endothelial function. n 6 cl, 1 ex, 1 tbl |
| priorityDate | 2011-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.